2. Academic Validation
  3. 18F-Facbc in Prostate Cancer: A Systematic Review and Meta-Analysis

18F-Facbc in Prostate Cancer: A Systematic Review and Meta-Analysis

  • Cancers (Basel). 2019 Sep 11;11(9):1348. doi: 10.3390/cancers11091348.
Riccardo Laudicella 1,  Domenico Albano 2,  Pierpaolo Alongi 3,  Giovanni Argiroffi 4,  Matteo Bauckneht 5,  Sergio Baldari 6,  Francesco Bertagna 7,  Michele Boero 8,  Giuseppe De Vincentis 9,  Angelo Del Sole 10,  Giuseppe Rubini 11,  Lorenzo Fantechi 12,  Viviana Frantellizzi 13,  Gloria Ganduscio 14,  Priscilla Guglielmo 15,  Anna Giulia Nappi 16,  Laura Evangelista 17,  on the behalf of Young AIMN Working Group 18
Affiliations

Affiliations

  • 1 Department of Biomedical and Dental Sciences and of Morpho-functional Imaging, Nuclear Medicine Unit, University of Messina, 98125 Messina, Italy. [email protected].
  • 2 Department of Nuclear Medicine, University of Brescia and Spedali Civili Brescia, 25123 Brescia, Italy. [email protected].
  • 3 Unit of Nuclear Medicine, Fondazione Istituto G.Giglio, 90015 Cefalù, Italy. [email protected].
  • 4 Department of Health Sciences, University of Milan, 20142 Milan, Italy. [email protected].
  • 5 Nuclear Medicine Unit, IRCCS Policlinico San Martino, 16132 Genoa, Italy. [email protected].
  • 6 Department of Biomedical and Dental Sciences and of Morpho-functional Imaging, Nuclear Medicine Unit, University of Messina, 98125 Messina, Italy. [email protected].
  • 7 Department of Nuclear Medicine, University of Brescia and Spedali Civili Brescia, 25123 Brescia, Italy. [email protected].
  • 8 Nuclear Medicine Unit, AO Brotzu, 09134 Cagliari, Italy. [email protected].
  • 9 Department of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza University of Rome, 00161 Rome, Italy. [email protected].
  • 10 Department of Health Sciences, University of Milan, 20142 Milan, Italy. [email protected].
  • 11 Nuclear Medicine Unit, Department of Interdisciplinary Medicine, University of Bari Aldo Moro, 70124 Bari, Italy. [email protected].
  • 12 Department of New Technologies and Translational Research in Medicine and Surgery, Nuclear Medicine Unit, University of Pisa, 56126 Pisa, Italy. [email protected].
  • 13 Department of Molecular Medicine, Sapienza University of Rome, 00185 Rome, Italy. [email protected].
  • 14 Unit of Nuclear Medicine, Fondazione Istituto G.Giglio, 90015 Cefalù, Italy. [email protected].
  • 15 Nuclear Medicine Unit, AO Brotzu, 09134 Cagliari, Italy. [email protected].
  • 16 Nuclear Medicine Unit, Department of Interdisciplinary Medicine, University of Bari Aldo Moro, 70124 Bari, Italy. [email protected].
  • 17 Nuclear Medicine Unit, Veneto Institute of Oncology IOV - IRCCS, 35128 Padua, Italy. [email protected].
  • 18 Department of Biomedical and Dental Sciences and of Morpho-functional Imaging, Nuclear Medicine Unit, University of Messina, 98125 Messina, Italy.
PMID: 31514479 DOI: 10.3390/cancers11091348
Abstract

Trans-1-amino-3-18F-fluorocyclobutanecarboxylic-acid (anti-[18F]-FACBC) has been approved for the detection of prostate Cancer (PCa) in patients with elevated prostate-specific-antigen following prior treatment. This review and meta-analysis aimed to investigate the diagnostic performance of 18F-FACBC positron emission tomography/computed-tomography (PET/CT) in the detection of primary/recurrent PCa. A bibliographic search was performed including several databases, using the following terms: "FACBC"/"fluciclovine" AND "prostate cancer"/"prostate" AND "PET"/"Positron Emission Tomography". Fifteen and 9 studies were included in the systematic reviews and meta-analysis, respectively. At patient-based analysis, the pooled sensitivity and specificity of 18F-FACBC-PET/CT for the assessment of PCa were 86.3% and 75.9%, respectively. The pooled diagnostic odds-ratio value was 16.453, with heterogeneity of 30%. At the regional-based-analysis, the pooled sensitivity of 18F-FACBC-PET/CT for the evaluation of primary/recurrent disease in the prostatic bed was higher than in the extra-prostatic regions (90.4% vs. 76.5%, respectively); conversely, the pooled specificity was higher for the evaluation of extra-prostatic region than the prostatic bed (89% vs. 45%, respectively). 18F-FACBC-PET/CT seems to be promising in recurrent PCa, particularly for the evaluation of the prostatic bed. Additional studies to evaluate its utility in clinical routine are mandatory.

Keywords

18F-FACBC; PET/CT; meta-analysis; prostate cancer; recurrence; review.

Figures
Products